Figure 2. Swimmer plot illustrating treatment, responses and acquired mutations in liquid biopsy cohort of 20 HNSCC patients treated with cetuximab plus chemotherapy.

Weeks of combination therapy with cis⁻ or carboplatin, 5-fluorouracil and cetuximab are shown in dark colors, weeks of cetuximab maintenance in light colors. • Complete response, ▼ partial response, — stable disease, ▲ progressive disease. Activating RAS mutations are mapped at the time of their first appearance. ¹Patients refused further treatment. ²Patient died of pneumonia. ³Therapy was stopped because of bleeding complications. → Ongoing treatment.